Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
复制标题
DOI：
10.4049/immunohorizons.1700063
复制
发表时间：
2018-07-02
期刊：
影响因子：
--
通讯作者：
Dowling, David J
中科院分区：
文献类型：
--
作者：
Dowling, David J
对新佐剂的需求对于新疫苗的开发和进一步优化当前的免疫方法是绝对重要的。然而，目前只有少数几类佐剂被掺入批准用于人的疫苗中。TLR激动剂作为疫苗佐剂的发现和递送的最新进展已经开始为疫苗学家打开新的工具箱。在这一运动的最前沿是使用合成的小分子TLR 7/8激动剂为基础的佐剂。在这篇综述中，我们强调了疫苗制剂科学在推动TLR 7/8佐剂性的最新发展中的重要性，总结了该领域中一些最新和最值得注意的研究，并讨论了下一代TLR 7/8佐剂用于增强脆弱人群（如非常年轻的人群）的疫苗应答的理想属性。最后，我们探索的进展，可能会进一步边缘的TLR 7/8免疫为基础的疫苗制剂的发展，对临床人体评价。
The need for new adjuvants is absolutely cardinal to the development of new vaccines and to further optimizing current immunization approaches. However, only a few classes of adjuvants are presently incorporated in vaccines approved for human use. Recent advances in the discovery and delivery of TLR agonists as vaccine adjuvants have begun to open up a new toolbox for vaccinologists. At the forefront of this movement is the use of synthetic small molecule TLR7/8 agonist-based adjuvants. In this review, we emphasize the importance of vaccine formulation science in driving recent developments in TLR7/8 adjuvanticity, summarize some of the most current and notable studies in this field, and discuss desirable attributes of next generation TLR7/8 adjuvants for use in enhancing vaccine responses in vulnerable populations, such as the very young. Finally, we explore advances that may further edge the development of TLR7/8 adjuvant-based vaccine formulations toward clinical human evaluation.